Sierra Capital’s Definium Therapeutics DFTX Stock Holding History

Sierra Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	–	–	418
2022 Q4	$0	Buy	+1	New	+$3	﹤0.01%	662

Other funds holding DFTX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Sierra Capital's DFTX Position: Q1 2023 in Review

Sierra Capital sold out of Definium Therapeutics (DFTX) in Q1 2023, closing a stake of 1 share.

Sierra Capital first reported a position in DFTX in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 88 funds tracked by Wall St. Rank hold DFTX as of Q1 2023.

Sierra Capital reported no remaining Definium Therapeutics position as of Q1 2023 after selling out during the quarter.
Sierra Capital sold 1 Definium Therapeutics share in Q1 2023.
Sierra Capital first reported a position in Definium Therapeutics in Q4 2022 and held it in 1 quarter.
Sierra Capital's Definium Therapeutics position peaked at $0 in Q4 2022.
88 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2023.

Based on Sierra Capital's 13F filing for Q1 2023, filed 1 May 2023.